Cerebellar Soluble Mutant Ataxin-3 Level Decreases during Disease Progression in Spinocerebellar Ataxia Type 3 Mice

被引:13
|
作者
Huu Phuc Nguyen [1 ]
Huebener, Jeannette [1 ]
Weber, Jonasz Jeremiasz [1 ]
Grueninger, Stephan [2 ]
Riess, Olaf [1 ]
Weiss, Andreas [2 ,3 ]
机构
[1] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany
[2] Novartis Inst BioMed Res, Basel, Switzerland
[3] IRBM Promidis, Pomezia, Italy
来源
PLOS ONE | 2013年 / 8卷 / 04期
关键词
BIOMARKER-DEVELOPMENT; NUCLEAR-LOCALIZATION; CLEAVAGE; AGGREGATION; HUNTINGTIN; PATHOGENESIS; PROTEOLYSIS; INHIBITION; MANIFESTATION; DEGENERATION;
D O I
10.1371/journal.pone.0062043
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph disease, is an autosomal dominantly inherited neurodegenerative disease caused by an expanded polyglutamine stretch in the ataxin-3 protein. A pathological hallmark of the disease is cerebellar and brainstem atrophy, which correlates with the formation of intranuclear aggregates in a specific subset of neurons. Several studies have demonstrated that the formation of aggregates depends on the generation of aggregation-prone and toxic intracellular ataxin-3 fragments after proteolytic cleavage of the full-length protein. Despite this observed increase in aggregated mutant ataxin-3, information on soluble mutant ataxin-3 levels in brain tissue is lacking. A quantitative method to analyze soluble levels will be a useful tool to characterize disease progression or to screen and identify therapeutic compounds modulating the level of toxic soluble ataxin-3. In the present study we describe the development and application of a quantitative and easily applicable immunoassay for quantification of soluble mutant ataxin-3 in human cell lines and brain samples of transgenic SCA3 mice. Consistent with observations in Huntington disease, transgenic SCA3 mice reveal a tendency for decrease of soluble mutant ataxin-3 during disease progression in fractions of the cerebellum, which is inversely correlated with aggregate formation and phenotypic aggravation. Our analyses demonstrate that the time-resolved Forster resonance energy transfer immunoassay is a highly sensitive and easy method to measure the level of soluble mutant ataxin-3 in biological samples. Of interest, we observed a tendency for decrease of soluble mutant ataxin-3 only in the cerebellum of transgenic SCA3 mice, one of the most affected brain regions in Spinocerebellar Ataxia Type 3 but not in whole brain tissue, indicative of a brain region selective change in mutant ataxin-3 protein homeostasis.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1
    Edamakanti, Chandrakanth Reddy
    Do, Jeehaeh
    Didonna, Alessandro
    Martina, Marco
    Opal, Puneet
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (06): : 2252 - 2265
  • [22] Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies
    Evers, Melvin M.
    Toonen, Lodewijk J. A.
    van Roon-Mom, Willeke M. C.
    MOLECULAR NEUROBIOLOGY, 2014, 49 (03) : 1513 - 1531
  • [23] Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3
    Johnson, Sean L.
    Libohova, Kozeta
    Blount, Jessica R.
    Sujkowski, Alyson L.
    Prifti, Matthew, V
    Tsou, Wei-Ling
    Todi, Sokol, V
    NEUROBIOLOGY OF DISEASE, 2021, 160
  • [24] Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder
    Raj, Kritika
    Akundi, Ravi Shankar
    MOLECULAR NEUROBIOLOGY, 2021, 58 (07) : 3095 - 3118
  • [25] Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood
    Hanna AL-Shaikh, Rana
    Jansen-West, Karen R.
    Petrucelli, Leonard
    Wszolek, Zbigniew K.
    Prudencio, Mercedes
    MOVEMENT DISORDERS, 2022, 37 (05) : 1120 - 1121
  • [26] Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model
    Bonanomi, Marcella
    Natalello, Antonino
    Visentin, Cristina
    Pastori, Valentina
    Penco, Amanda
    Cornelli, Giuseppina
    Colombo, Giorgio
    Malabarba, Maria G.
    Doglia, Silvia M.
    Relini, Annalisa
    Regonesi, Maria E.
    Tortora, Paolo
    HUMAN MOLECULAR GENETICS, 2014, 23 (24) : 6542 - 6552
  • [27] Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
    Sutton, Joanna R.
    Blount, Jessica R.
    Libohova, Kozeta
    Tsou, Wei-Ling
    Joshi, Gnanada S.
    Paulson, Henry L.
    Costa, Maria do Carmo
    Scaglione, K. Matthew
    Todi, Sokol V.
    HUMAN MOLECULAR GENETICS, 2017, 26 (08) : 1419 - 1431
  • [28] Reply to: "Comment on: Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood"
    Huebener-Schmid, Jeannette
    Kuhlbrodt, Kirsten
    Peladan, Julien
    Riess, Olaf
    MOVEMENT DISORDERS, 2022, 37 (05) : 1121 - 1122
  • [29] Repeat length and disease progression in spinocerebellar ataxia type 3
    Klockgether, T
    Kramer, B
    Ludtke, R
    Schols, L
    Laccone, F
    LANCET, 1996, 348 (9030): : 830 - 830
  • [30] Trehalose prevents the formation of aggregates of mutant ataxin-3 and reduces soluble ataxin-3 protein levels in an SCA3 cell model
    Wang, Zijian
    Wang, Min
    Huang, Yuhang
    Ma, Zhiwei
    Gao, Wenjing
    Zhang, Tian
    Deng, Jiexin
    Cheng, Xiaoxia
    Liu, Yingxun
    Wang, Bo
    Qi, Ying
    Yang, Min
    He, Fengqin
    NEUROSCIENCE, 2024, 555 : 76 - 82